New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
10:59 EDTOHRP, RHT, SWHC, BBRY, MTOR, PIR, SBGI, ARWR, VRTX, JBLOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ARWR SBGI PIR MTOR BBRY SWHC RHT JBL
News For OHRP;VRTX;ARWR;SBGI;PIR;MTOR;BBRY;SWHC;RHT;JBL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
10:00 EDTSWHCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:46 EDTBBRYBlackBerry implied volatility of 55 at lower end of index mean range
Subscribe for More Information
06:37 EDTSWHCSmith & Wesson initiated with a Buy at Wunderlich
Subscribe for More Information
October 16, 2014
08:01 EDTRHTRed Hat, Cloudera announce alliance to deliver enterprise software solutions
Subscribe for More Information
06:09 EDTBBRYBlackBerry implied volatility of 56 at lower end of index mean range
Subscribe for More Information
October 15, 2014
09:57 EDTARWRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:06 EDTARWRArrowhead pullback since ARC-520 data an overreaction, says Piper Jaffray
Subscribe for More Information
October 14, 2014
14:54 EDTARWRQVT Financial raises passive stake in Arrowhead to 7.62% from 5.29%
Subscribe for More Information
13:59 EDTVRTXVertex mentioned cautiously at BofA/Merrill
07:19 EDTOHRPOhr Pharmaceutical announces successful end of Phase II meeting with FDA
Ohr Pharmaceutical announced details of the planned pivotal Phase III registration trials for Squalamine Eye Drops, or OHR-102, in the treatment of wet age-related macular degeneration, or wet AMD. The trials are being designed based on guidance provided by the FDA at a recent "end of Phase II" meeting. The FDA has agreed with Ohr on a 9 month primary efficacy endpoint based on the proportion of patients achieving a greater than or equal to 3 line gain in visual acuity. In the interim analysis of the ongoing Phase II IMPACT study, more than twice the proportion of patients achieved greater than or equal to 3 line gains in visual acuity at 9 months with the combination of OHR-102 eye drops and Lucentis as compared to the Lucentis monotherapy group. Two identical Phase III studies will be performed. The company plans to initiate the Phase III trials in the first half of 2015 with the goal of submitting a New Drug Application following collection and analysis of the 9 month primary efficacy data.
October 13, 2014
10:08 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTVRTXVertex price target raised to $131 from $119 at RW Baird
Subscribe for More Information
07:46 EDTBBRYBlackBerry second half hardware estimates lowered at Canaccord
Canaccord lowered its second half of 2015 hardware estimates for Blackberry after surveys show limited availability of its new Passport smartphone. The firm, however, expects improving trends and believes Blackberry will achieve its target of reaching break-even cash low levels. Canaccord maintains its Hold rating and $10 price target on Blackberry shares.
07:12 EDTARWROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
05:35 EDTVRTXVertex upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Vertex Pharmaceuticals to Overweight citing likely approval of the company's Kalydeco plus lumacaftor combination next year. Piper expects Vertex's Cystic Fibrosis sales to grow to $3.1B in 2016 and raised its price target for shares to $125 from $87.50.
October 10, 2014
12:11 EDTARWROptions with increasing implied volatility
Subscribe for More Information
08:48 EDTSBGISinclair Broadcast has positive catalysts, fears overdone, says RBC Capital
Subscribe for More Information
08:24 EDTVRTXVertex price target raised to $117 from $109 at Maxim
Maxim raised its price target for Vertex shares to $117 after the company gave an update at the Cystic Fibrosis Conference. The form keeps a Buy rating on the stock.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use